Bortezomib Suppliers & Bulk Manufacturers
Available Forms: Injection (lyophilized powder for solution)
Available Strengths: 1 mg/vial, 3.5 mg/vial
Reference Brands: Velcade® (US & EU)
Category: Oncology Cancer Care
Bortezomib is available in Injection (lyophilized powder for solution) and strengths such as 1 mg/vial, 3.5 mg/vial. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Bortezomib is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.
| Technical Specifications & Supply Details | |
|---|---|
| Lead Time | 7 to 60 days (depending on batch size & schedule) |
| MOQ | As per manufacturer’s batch size |
| COA | Available with every batch |
| Regulatory Dossier / DMF | Available upon request |
| Export Documentation | FSC, COA, Manufacturing License, Product Permission |
| Standards | IP, BP, USP |
| Certifications | WHO-GMP, EU-GMP, USFDA (as applicable) |
Bortezomib can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Product Description: Bortezomib Injection, available in 1 mg and 3.5 mg lyophilized vials, is a leading oncology drug used for multiple myeloma and mantle cell lymphoma in the EU and US markets. As a proteasome inhibitor, Bortezomib disrupts protein degradation in cancer cells, inducing apoptosis and inhibiting tumor growth. Marketed under the brand Velcade®, this essential anticancer agent is available for IV and subcutaneous use. GMP-compliant manufacturers supply Bortezomib as a sterile injectable formulation, making it a high-demand product for pharmaceutical B2B sourcing, licensing, and global distribution in regulated markets.
Frequently Asked Questions
Related Products
Atezolizumab
Strength:
1200 mg/20 mL
Form: Intravenous infusion
Reference Brands: Tecentriq® (EU & US)
View Details
Durvalumab
Strength:
120 mg/4 mL, 500 mg/10 mL
Form: Injection
Reference Brands: Imfinzi® (US & EU)
View Details
Sunitinib
Strength:
12.5 mg, 25 mg, 37.5 mg, 50 mg
Form: Tablet
Reference Brands: Sutent® (EU & US)
View DetailsQuick Response Guaranteed | Verified Suppliers
